Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

patient expectations

Menopause

Breaking the silence: It’s time to talk about the menopause

Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change.

Inizio

regeneron headquarters

FDA accepts Regeneron’s REGEN-COV for priority review for treatment of COVID-19

In Europe, the EMA will review a Marketing Authorisation Application for the antibody cocktail

- PMLiVE

New data shows Roche’s Enspryng significantly reduces neuromyelitis optica spectrum disorder relapses

Enspryng is the first and only NMOSD treatment administered subcutaneously every four weeks

- PMLiVE

Beyond yoga and smoothies – providing real support for employee well-being

Virtual exercise class, yoga, smoothie-making competition? Walkathon, anyone? It can only be Well-being Week!With World Mental Health Day on Sunday 10th October, this week felt like a great time to...

Nucleus Global

Driving Healthcare Decisions with Natural Language Processing

Dr. Sabita Sankar, VP of Business Development at HUMA.AI, discusses “human-centric AI” and how to automate healthcare through human language, with special focus on the applications for Medical Affairs, Clinical,...

Impetus Digital

- PMLiVE

FDA approves Eli Lilly’s Verzenio in high risk early breast cancer

Verzenio is the first addition to adjuvant endocrine therapy approved by the FDA in nearly two decades for the treatment of HR+ HER2- early breast cancer

- PMLiVE

Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS

The data presented at ECTRIMS 2021 reinforces the efficacy and safety profile of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis

Graphic showing light bulbs with numbers on

Committing time to making meaningful connections – top 5 tips

Read the second blog of the series looking at key barriers to effective patient engagement in pharma

Cuttsy + Cuttsy

News:

Senior Analytics Specialist joins Research Partnership

Inizio

Sanofi reception

Sanofi’s tolebrutinib demonstrates favourable one-year tolerability in patients with relapsing forms of multiple sclerosis

New long-term data presented at ECTRIMS 2021 reinforces promising safety and efficacy profile

Biogen Idec building

Data shows patients treated with Biogen’s MS therapies mount an effective antibody response to COVID-19 vaccination

New MS PATHS data was presented at ECTRIMS 2021

- PMLiVE

Healthcare creatives need to be more like Bryson

By James Mayfield

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links